Klaus Mörike

Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles of <i>CYP2D6</i> in a European Population

Franck Broly, Andrea Gaedigk, Markus H. Heim et al. · DNA and Cell Biology · 1991 · 223 citations

Medicine, Genetics, Pharmacology +17

Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.

Denis M. Grant, Klaus Mörike, Michel Eichelbaum et al. · Journal of Clinical Investigation · 1990 · 127 citations · Full text

Medicine, Pharmacology, Biochemical Pharmacology +13

Impact of genotype on adverse effects during treatment with metoprolol: A prospective clinical study

Richard Fux, Klaus Mörike, Anne Marie Theres Pröhmer et al. · Clinical Pharmacology & Therapeutics · 2005 · 126 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers

Dieter Schrenk, D. Brockmeier, Klaus Mörike et al. · European Journal of Clinical Pharmacology · 1998 · 117 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +5

Dose‐Proportional Intraindividual Single‐ and Repeated‐Dose Pharmacokinetics of Roflumilast, an Oral, Once‐Daily Phosphodiesterase 4 Inhibitor

Thomas D. Bethke, Gabriele M. Böhmer, Róbert Hermann et al. · The Journal of Clinical Pharmacology · 2006 · 91 citations

Pharmacy, Pharmacokinetics, Pharmacology +13